There have been some issues however with the outsourcing of trials to CROs, including serious relationship break down with negative attitudes, failure to communicate between to the partners and some claiming CROs do not ‘get in the spirit’ of the research following only the letter of the contract.
Don’t miss SMi’s 4th annual Managing Partnerships with CROs conference that will provide delegates with a comprehensive overview and analysis of outsourcing in the pharmaceutical sector.
Providing key opportunities to associate with representatives from CROs, Big Pharma and Academia, the meeting will highlight the real time issues with CRO - Pharma partnerships, up to date case studies will provide emphasis on improving relationships and tips on enhancing communication and creating long and successful partnerships.
Key benefits of attending:
Discuss the strategic rationale for clinical development outsourcing among the large pharmaceutical companies.
Network and discuss ideas with key decision makers in pharma / biotech / CROs.
Hear from industry experts about the current issues with CRO partnership.
Learn what clinical development capabilities do various companies consider core and noncore, and how is this changing?
Investigate to what extent is the design of relationships and associated capabilities aligned with strategic intent
Develop strategy in relationship structures and how you can modify your own relationships.
Two highly rated workshops, Peter Volker from Booz & Co the company that recently released a highly rated report with CRO ICON. Dr. Volker will discuss key issues on preparing for partnership and engagement models and success factors and Graeme Ladds who has worked with CROs for many years had developed his workshop to touch upon points for success, strategy for maintaining quality and multinational multiproduct outsourcing.
For more information visit http://www.smi-